[
    [
        {
            "time": "2018-01-02",
            "original_text": "Elanco Announces Addition of New North America and Global Strategy Senior Executive",
            "features": {
                "keywords": [
                    "Elanco",
                    "North America",
                    "Global Strategy",
                    "Senior Executive"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Elanco Announces Addition of New North America and Global Strategy Senior Executive",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Big Pharma CEOs Speak About Impact of Tax Reform on M&A",
            "features": {
                "keywords": [
                    "Big Pharma",
                    "CEOs",
                    "Tax Reform",
                    "M&A"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Big Pharma CEOs Speak About Impact of Tax Reform on M&A",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "How Mylan’s Rest of the World Segment Performed in 3Q17",
            "features": {
                "keywords": [
                    "Mylan",
                    "Rest of the World",
                    "Segment Performance",
                    "3Q17"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "How Mylan’s Rest of the World Segment Performed in 3Q17",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe",
            "features": {
                "keywords": [
                    "Elanco",
                    "Aratana",
                    "GALLIPRANT",
                    "Marketing Authorization",
                    "Europe"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]